Hybrid Materials Handler, Contract bei Delfi diagnostics, inc.
Delfi diagnostics, inc. · Palo Alto, CA, Vereinigte Staaten Von Amerika · Hybrid
- Optionales Büro in Palo Alto, CA
About the Role
DELFI Diagnostics is seeking an exceptional Material Handler II with BioTechnology experience to join our growing organization. The Material Handler II hours of operation will be from Tuesday through Saturday 8:00am-4:30pm.
Reporting to the Director of Facilities, we are seeking an experienced Material Handler II who has a wide range of experience to support the company’s continued growth. The selected candidate will own day-to-day inventory management, including but not limited to: MRP (material requirement planning) purchase order receipts (patient samples, reagents, consumables, furniture, critical equipment etc..), inventory adjustments, inventory lab fulfillment, kanban fulfillment, qualified materials movements, cycle counts, MSS (Material Specification Sheet) process, patient sample receipts, and resolving purchase order and invoice discrepancies. The Material Handler II will also work cross-functionally with laboratory personnel to ensure all labs are fully operational and well supplied with materials to minimize disruptions, and will frequently collaborate with Clinical, R&D, IT, Legal, Procurement, and Accounting teams as well. This person will embody our values, champion data-driven decision making, and partner clearly and effectively across functions.
Shift: Monday to Friday morning shift (Tuesday - Saturday as needed)
Contractor Duration: 6 months
About Us
DELFI Diagnostics, Inc. (DELFI Diagnostics) is developing next-generation, blood-based tests that are reliable, accessible and deliver a new way to help detect cancer. Employing advanced machine-learning methods to whole-genome sequencing data, the DELFI ("DNA EvaLuation of Fragments for early Interception") platform is built to address the highest-burden health challenges. DELFI Diagnostics prioritizes solutions that have the potential to save lives on a global scale, including for historically underserved populations. DELFI Diagnostics’ platform relies on fragmentomics – the discovery that cancer cells are more chaotic than normal cells and, when they die, leave behind tell-tale patterns and characteristics of cell-free DNA (cfDNA) fragments. FirstLook Lung, for individuals eligible for lung cancer screening, is DELFI Diagnostics’ first laboratory-developed screening test and can be part of routine blood work. FirstLook Lung uses millions of data points to reliably identify individuals who may have cancer detected through low-dose CT, including early stage disease with a negative predictive value of 99.7 percent. This test has not yet been cleared or approved by the FDA.
In our passionate pursuit to radically improve health outcomes, we serve humanity when we:
Lead with Science, Anchor in Pragmatism: We pioneer life-changing science by ensuring quality, transparency, and rigor at all times. We explore thoughtfully, experiment smartly, and deliver impact with conviction.
Build With & For All: We embrace diverse backgrounds to innovate and achieve together. We are not just building a product - we aim to disrupt the path of cancer for all - no matter geography or socioeconomic class
Put We over I: We are a home for high-performing people. Through teamwork, we build collective intelligence. Each of us wins when those we serve and those who serve with us--win. We show up with empathy, humility, and integrity at every step of the journey.
